Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

NASDAQ:CRDF

Overview | Financials
Company Name Cardiff Oncology, Inc.
Symbol CRDF
Currency USD
Price 3.92
Market Cap 260,752,128
Dividend Yield 0%
52-week-range 1.41 - 6.42
Industry Biotechnology
Sector Healthcare
CEO Dr. Mark Erlander Ph.D.
Website https://www.cardiffoncology.com

An error occurred while fetching data.

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias;

Related Stocks

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.454 USD

Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

ALGS

39.34 USD

Cryo-Cell International, Inc. logo

Cryo-Cell International, Inc.

CCEL

7.75 USD

Reneo Pharmaceuticals, Inc. logo

Reneo Pharmaceuticals, Inc.

RPHM

18.2 USD

Vaccinex, Inc. logo

Vaccinex, Inc.

VCNX

1.18 USD

Daxor Corporation logo

Daxor Corporation

DXR

7.95 USD

Financials

Numbers are in millions USD

Numbers are in millions USD